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The article entitled “Periprosthetic leak and rup-
ture after endovascular repair of abdominal aortic
aneurysm: The significance of device design for
long-term results” by Krohg-Sørensen et al and the
invited commentary by Zarins in this issue bring up
a serious concern regarding endograft repair of
abdominal aortic aneurysms (AAA)—namely, the
problem of obtaining up-to-date and complete
information on the performance of the devices that
are undergoing clinical trial. Of particular concern is
that a major part of this problem may be related to
the control of trial data by industry.
The delay between completion of a study, analy-
sis of the data, and submission and publication of the
manuscripts may be considerable. Consequently, the
practicing surgeon may lack information to guide
safe and proper patient management. Even those
surgeons not directly involved in this new technolo-
gy need this information to determine the best cur-
rent management for their patients with AAA and to
possibly refer those patients for endograft repair or
enlist them into a particular trial. This delay in
release of information is understandable in blinded
randomized drug trials but should not be a problem
in the trials of AAA endograft devices, which cannot
be blinded and which, up to now, have not been ran-
domized. Data are being collected steadily, and
information is potentially available throughout all
phases of these trials. This should be straightforward
if a data monitoring committee is provided with
information, including complications, on a regular
basis. It is just a matter of what information is dis-
seminated and how and of how frequent and com-
plete the reports are. Let us look at what has hap-
pened so far in this new field.
First, there has been a tendency to “hype” this
new technology from the beginning. It is natural for
both the primary investigators and the company to
want others to share their enthusiasm for the new
technology. In early presentations of the data at con-
ferences and symposia, the unlikelihood of being
held responsible for what is said, as compared with
what is printed in a submitted manuscript, encour-
ages speculative claims that the subsequent data may
not support. With the numerators and denominators
changing quickly with each update, it has been diffi-
cult for those not intimately involved in these trials
to develop an accurate perspective on mortality and
major morbidity rates, the rate and fate of endoleaks,
etc. However, because the data should be collected
in such a way to be suitable for publication, there is
no reason why full and accurate reports of nonpro-
prietary information cannot or should not be regu-
larly presented at such meetings and symposia, with
objective reporting practices, just as one would at a
national or regional society meeting where the paper
is discussed and peer reviewed. This would reduce
much of the unfounded speculations and misleading
impressions that have characterized many of the
early presentations of these new devices.
At the beginning, particularly in the active patient
recruitment phase, information is usually readily
obtained as data from investigator’s meetings are
allowed to be presented elsewhere by them. Later, it is
common practice that only “official” data releases are
allowed. Sometimes, as happened with Endovascular
Technologies (EVT), restrictions on data release are
explained by the need for compliance with inside trad-
er rules, if the company has gone public, but when
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information available outside investigator’s meetings is
limited to periodic press releases, which amount to
limited views of outcome data intended more for
investors than investigators, scientific progress and
integrity is not being served. If periodic open and uni-
form release of data is the avowed goal (to comply
with inside trader rules), there is no reason, outside of
the obvious self-serving one, that the data released
cannot be full and complete and the intervals reason-
ably frequent. The details of the device and its deploy-
ment are indeed proprietary, and objective data from a
clinical trial should not be so considered. The principle
investigators and the company should feel a responsi-
bility to do this. 
Eventually, publications begin to appear—often
multiple publications on each device. It is under-
standable if multiple publications arise during a long
three-phase trial of a new device. One of the prob-
lems with multiple publications of the same longitu-
dinal data is that subsequent accounts may have dif-
ferent starting points, ostensibly because the device
itself, or the deployment system, has undergone
redesign and reengineering and with the understand-
able intent that the method gets full credit for such
improvements. However, this practice also hides the
learning curve. The “hook breaks” may have seemed
like a disaster to the EVT trial, and potentially were,
but now reporting only data since the trial recom-
menced in November 1995 has been a blessing. It is
not that it is inappropriate to show the effect of
improvements in the device or the skills of those
implanting it but that it is more appropriate to pre-
sent the entire experience and make those points by
subgroup analysis and let the reader be the judge. 
Unfortunately, it appears that some of those
investigators who present data on company-spon-
sored clinical trials have not been close to the data
collection or analysis and have not performed or
checked the statistical analyses. In some cases, they
have not been able to supply key additional infor-
mation requested by discussants or reviewers.
Having the data primarily handled by the company
and analyzed by it has other potentially serious
drawbacks. The main reason for regular, prompt,
and complete disclosures of the outcomes of new
devices is not so much to allow comparison of tech-
nical success rates, procedural mortality rates, and
average length of stay in the hospital, the outcome
criteria featured in most early reports because prop-
er comparison necessitates long-term data. Rather it
is to fulfill the need to assess the failure rates and
major complications and their severity and impact,
because ultimately, patient safety is at stake. This
cannot be accomplished by carefully controlled
releases of selected data intended to place the device
in the best light. Even periodic investigator meetings
may not fulfill this need when the data are prepared
and presented by company officials or when the
investigators are instructed not to disseminate the
information. 
Serious device complications, or design and fab-
rication flaws that can potentially lead to them,
should be reported immediately rather than when it
is apparent beyond reasonable doubt that the device
is guilty of producing serious complications. Such
was the case with the hook fractures that occurred
with the EVT device, which were promptly dis-
closed. A public announcement was made, the
details were published widely to surgeons,1 and the
trial was stopped and not resumed until the Food
and Drug Administration was satisfied that reengi-
neering had solved the problem.
When fabrication flaws were detected in another
commonly used device, the Min Tec Stentor graft,
some of us learned of disappearing (breaking)
sutures from leaked discussions at investigator meet-
ings well over a year before public acknowledgment
came at meetings or, finally, in a publication.2 This
European report of seven explanted Stentor endo-
grafts showing “17-40% of the (polypropylene) liga-
tures of the body middle ring to be loose” and six of
the seven with breakage, dislocation, endoleak, or
occlusion was not published until this January. Just
2 months before this report was published, a pre-
sentation of the Eurostar data3 reported a late
endoleak rate of 2% to 10% per 6-month interval and
the observation that “breakage of polypropylene
sutures connecting the rings of the metal stent frame
has recently been observed in one of the commer-
cially available types of endografts.” The device was
pointedly not identified in the syllabus or presenta-
tion, purportedly because of an understanding with
those funding the Eurostar registry that the data not
be stratified and identified by specific device when
presented and published by those running the reg-
istry. It was also noted in this presentation that a
prospective study of 98 patients with this device at
nine institutions showed breakage of multiple
sutures in 37%. Five percent of the patients studied
had endoleaks develop. Without presenting the
details of the analysis that allowed them to draw
their conclusions, the authors made the following
cautious statements “… there was no correlation
between suture breakage and the degree of angula-
tion of the device (and) … no correlation …
between device related endoleaks (and) suture
JOURNAL OF VASCULAR SURGERY
1168 Rutherford June 1999
breakage.” Other slightly earlier reports contained
such statements as “no adverse events have been
attributable to this observation” and “the clinical
significance of this observation is unknown.”
Min Tec’s Stentor device has, of course, been
taken over by Boston Scientific Corporation and has
been superseded by the similar, but redesigned and
differently fabricated, Vanguard device. So, one
might assume that the suture breakage problem has
been solved. In this issue, a case of a Vanguard graft
has been reported4 in which “a periprosthetic leak
caused by a tear in the polyester prosthesis appeared
between 9 and 12 months after surgery.” The tear
appeared adjacent to a suture breakage, causing sep-
aration of two struts of the nitinol wire framework in
the body of the stentgraft. In this article, the authors
point out “In this device, the metal components can
move freely related to the covering fabric. When the
sutures break, there might be a risk that the apex of
a zigzag stent could angle into the fabric and cause
focal wear.” Later in the discussion, they point out
that “According to the manufacturer of this device,
suture breakage with separation of metal components
is commonly seen, but perforation of the polyester
prosthesis caused by movement of the metal stent
against the fabric has not been reported.” However,
in an addendum to the revised manuscript they state
“In November 1998, after this manuscript was pre-
pared, we received an important message from
Boston Scientific Corporation sent to all customers.
Apparently, late endoleaks caused by holes in the fab-
ric covering now have been reported to the manu-
facturer in six cases, and ‘Investigations show that the
failures are due to focal wear at the apex of a nitinol
stent “zig” against the graft fabric.’” Other signifi-
cant statements in this letter not included in this arti-
cle are: “The reported events occurred between five
and twelve months post-implant (which) suggests
that the incidence will (not) increase with time” and
“only one of the events described in this letter
occurred within the Eurostar data set.” However,
five of these six cases were discussed by Dr Hugh G.
Beebe when presenting an update on the United
States Vanguard Endograft Trial at a breakfast session
at the Montefiore Symposium last November. This
may yet be simply a new and relatively low frequency
form of endoleak with this device. However, subse-
quently the Safety Committee of the Dutch Society
for Vascular Surgery has advised its members to stop
implanting this device, although the appropriate
action is, at this writing, still under consideration by
a safety committee. The fact that this author was able
to piece together most of the additional information
included above by attending certain meetings and
making personal contacts does not diminish the
awareness gap that exists for much of the vascular
community.
The issue of early if not immediate disclosure of
possible device failures remains an important one.
How else can investigators be certain that it is safe
and ethical to continue the trial, and how else can
practicing surgeons be sure that it is safe to refer
their patients with AAAs for implantation of a par-
ticular endograft or, if they have appropriate
endovascular skills, begin using a device that is being
marketed? The entire issue of the control of clinical
trials and their data by industry deserves scrutiny
and will be the subject of another editorial in this
journal.
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Please see the related article by Krohg-Sørensen
et al on pages 1152-8.
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